EGFR-IN-214

Overview

EGFR-IN-214 is an orally active EGFR inhibitor with an EC 50 of 3.353 μM. EGFR-IN-214 blocks the downstream PI3K/Akt signaling pathway, induces intracellular ROS accumulation and Caspase -dependent apoptosis . EGFR-IN-214 exhibits antiproliferative activity in cancer cells and inhibits tumor growth in xenograft models. EGFR-IN-214 can be used in studies related to hepatocellular carcinoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Hepatitis B Virus Related Hepatocellular Carcinoma | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-184311
• CAS No.: 3077316-17-4
• Molecular Formula: C39H37F3N2O11
• Molecular Weight: 766.71
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source